Term
|
Definition
- Thorazine
- Low potency drug (100mg)
- Dose Range(mg/day) : 60-2000
- Maximum Dose: 2000mg
- Adverse Effects
- Sedative and ACh- High
- EPS- Low
- Hypotension- IM=high; PO=Mod.
- CYP metabolism: 2D6;1A2;3A4
- CYP inhibition: 2D6;2E1
|
|
|
Term
|
Definition
- Prolixin
- High potency (2mg)
- Dose Range: 1-50
- Max. Dose: 100mg
- Adverse Effect
- Low Sedative, ACh, & Hypotensive
- High EPS
- CYP metabolism:2D6
- CYP inhibition: 1A2;2C9;2D6;2E1
|
|
|
Term
|
Definition
- Haldol
- High potency (2mg)
- Dose Range: 1-100mg
- Max Dose: 100mg
- Adverse Effect
- Very low- Sedative, ACh, Hypotensive
- Very High EPS
- CYP metabolism:2D6;1A2;3A4
- CYP inhibition: 2D6;3A4
|
|
|
Term
|
Definition
- Loxitane
- Medium potency (10mg)
- Dose Range: 20-250mg
- Max. Dose: 250mg
- Adverse Effect
- Moderate- Sedative, EPS, hypotensive
- Low- ACh
- CYP metabolism: Extensive
- CYP inhibition: Unknown
|
|
|
Term
|
Definition
- Moban
- Medium Potency (10mg)
- Dose Range: 15-225
- Max Dose: 225
- Adverse effect
- Very low- Sedative
- Low- ACh and Hypotensive
- Moderate- EPS
- CYP metabolism:2D6
- CYP inhibition: unknown
|
|
|
Term
|
Definition
- Trilafon
- Medium potency (8-10mg)
- Dose Range: 8-64mg
- Max Dose: 100mg
- Adverse Effect
- Low- Sedative, ACh, Hypotensive
- High-EPS
- CYP metabolism: 2D6
- CYP inhibition: 2D6
|
|
|
Term
|
Definition
- Orap
- High potency (2mg)
- Dose Range: 2-10
- Max dose: 20mg
- Adverse effect
- Very low- Hypotensive
- Low- Sedative, ACh
- High- EPS
- CYP metabolism: 3A4;1A2
- CYP inhibition: 2D6
|
|
|
Term
|
Definition
- Mellaril
- Low potency (100mg)
- Dose Range: 50-800mg
- Max Dose: 800mg
- Adverse effect
- Low- EPS
- High- Sedative, ACh, Hypotensive
- CYP metabolism: 2D6;2C19
- CYP inhibition: 2D6;1A2;2C9,2E1
|
|
|
Term
|
Definition
- Navane
- Medium potency (4mg)
- Dose Range: 5-60mg
- Max Dose: 100mg
- Adverse effect
- Low- Sedative, ACh, Hypotensive
- High- EPS
- CYP metabolism: 1A2
- CYP inhibition: 2D6
|
|
|
Term
|
Definition
- Stelazine
- Medium Potency (5mg)
- Dose Range: 2-80mg
- Max. Dose: 100mg
- Adverse effect
- Low- Sedative, ACh, Hypotensive
- High- EPS
- CYP metabolism: 1A2
- CYP inhibition: No known
|
|
|
Term
Pharmacokinetics of all FGA |
|
Definition
- Renal insufficiency may require decreased dose
- Use with caution in pts with liver dysfunction
|
|
|
Term
|
Definition
- t1/2=12-36hrs
- tmax= 2-6hrs oral; 7 days decanoate
- Metabolized by CYP 1A2, 2D6,3A4
|
|
|
Term
|
Definition
- t1/2=8-35hrs
- Metabolized by liver enzymes CYP 3A4, 2D6 and conjugation
- Highly protein bound
- Chlorpromazine, Fluphenazine, Perphenazine, Thioridazine, Thiothixene, Trifluoperazine
|
|
|
Term
|
Definition
- Biphasic T1/2
- Initial- 5hrs
- Terminal- 12-19hrs
|
|
|
Term
|
Definition
- t1/2 >24hrs with chronic use
|
|
|